Carbohydrates and insulin resistance in clinical nutrition: Recommendations from the ESPEN expert group.

Détails

ID Serval
serval:BIB_CA0F054B95AB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Carbohydrates and insulin resistance in clinical nutrition: Recommendations from the ESPEN expert group.
Périodique
Clinical nutrition
Auteur(s)
Barazzoni R., Deutz NEP, Biolo G., Bischoff S., Boirie Y., Cederholm T., Cuerda C., Delzenne N., Leon Sanz M., Ljungqvist O., Muscaritoli M., Pichard C., Preiser J.C., Sbraccia P., Singer P., Tappy L., Thorens B., Van Gossum A., Vettor R., Calder P.C.
ISSN
1532-1983 (Electronic)
ISSN-L
0261-5614
Statut éditorial
Publié
Date de publication
04/2017
Peer-reviewed
Oui
Volume
36
Numéro
2
Pages
355-363
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Growing evidence underscores the important role of glycemic control in health and recovery from illness. Carbohydrate ingestion in the diet or administration in nutritional support is mandatory, but carbohydrate intake can adversely affect major body organs and tissues if resulting plasma glucose becomes too high, too low, or highly variable. Plasma glucose control is especially important for patients with conditions such as diabetes or metabolic stress resulting from critical illness or surgery. These patients are particularly in need of glycemic management to help lessen glycemic variability and its negative health consequences when nutritional support is administered. Here we report on recent findings and emerging trends in the field based on an ESPEN workshop held in Venice, Italy, 8-9 November 2015. Evidence was discussed on pathophysiology, clinical impact, and nutritional recommendations for carbohydrate utilization and management in nutritional support. The main conclusions were: a) excess glucose and fructose availability may exacerbate metabolic complications in skeletal muscle, adipose tissue, and liver and can result in negative clinical impact; b) low-glycemic index and high-fiber diets, including specialty products for nutritional support, may provide metabolic and clinical benefits in individuals with obesity, insulin resistance, and diabetes; c) in acute conditions such as surgery and critical illness, insulin resistance and elevated circulating glucose levels have a negative impact on patient outcomes and should be prevented through nutritional and/or pharmacological intervention. In such acute settings, efforts should be implemented towards defining optimal plasma glucose targets, avoiding excessive plasma glucose variability, and optimizing glucose control relative to nutritional support.

Mots-clé
Blood Glucose/metabolism, Carbohydrate Metabolism, Diet, Dietary Carbohydrates/administration & dosage, Dietary Carbohydrates/adverse effects, Evidence-Based Medicine, Glycemic Index, Humans, Hyperglycemia/etiology, Hyperglycemia/therapy, Hypoglycemia/etiology, Hypoglycemia/therapy, Insulin Resistance, Italy, Nutrition Policy, Nutritional Requirements, Nutritional Support, Risk Factors, Societies, Scientific, Carbohydrates, Clinical nutrition, Insulin resistance
Pubmed
Web of science
Création de la notice
11/10/2016 18:16
Dernière modification de la notice
20/08/2019 16:45
Données d'usage